UMGCC Research Program:
Experimental Therapeutics Program
Education/Training:
College Degree:
General Gymnasium, Split, Croatia
Medical Degree:
University of Zagreb School of Medicine, Zagreb, Croatia
Residency:
Lenox Hill Hospital, New York, NY
Fellowship:
University of Maryland School of Medicine, Baltimore, MD
Certification:
Internal Medicine, Hematology, and Oncology
Contact
Information:
Mailing Address:
University of Maryland Greenebaum Cancer Center
Room S9D04C
22 S. Greene Street
Baltimore, MD 21201
Email:
igojo@umm.edu
Phone:
410-328-2594
Fax:
410-328-6896
Research Interests:
Dr. Gojos clinical interest is in the diagnosis and treatment of all forms of leukemia, including acute myeloid, promyelocytic, and lymphoid leukemia, chronic myeloid leukemia, myeloproliferative and myelodysplastic disorders. Dr.Gojos research interests are in designing and conducting clinical trials with a goal to develop new treatment strategies that will improve outcome of patients with hematologic malignancies. As such, she serves as a principal investigator on several clinical trials, some of which are developed at UMGCC and some are part of multicenter effort. These clinical trials incorporate many new drugs given either alone or in combination with already established agents. These trials are designed for patients with different types and stages of leukemias including those that were recently diagnosed or have relapsed after previous treatment. Goal of these studies is to examine whether the novel therapeutic approaches might improve the outcome of patients with leukemia, and in long-term, will serve as a basis for further development of new therapeutic strategies in patients with hematologic malignancies.
Publications:
Karp, J.E., Gojo, I., Gocke, C.D., Guo, C., Greer, J., Tidwell, M., Zwiebel, J., and Chen, H.: Targeting vascular endothelial growth factor (VEGF) for relapsed and refractory adult acute myelogenous leukemias: timed sequential therapy with the anti-VEGF monoclonal antibody Bevacizumab. Clin Cancer Res, 10(11): 3577-85, 2004.
Gojo, I., Guo, C., Meisenberg, B., Sarkodee-Adoo, C., Fassass, A., Rapoport, A., Fox, M., Heyman, M., and Tricot, G.: High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant, 34(1): 69-76, 2004.
Gore, S. D., Smith, B.D., Gojo, I., Grever, M., Letendre, L., Leonard, D., Marcucci, G., Miller, C.B., Morris, L., Piantadosi, S., Prior, T., Stock, W., and Karp, J.E.: Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J of Hematol, 79(2):119-27, 2005.
Tummala, M., Thomas, L., Gocke, C., Heyman, M., Gojo, I.: Unusual leukemia presentations. Case2. Granulocytic sarcoma of the colon. J Clin Onc, 23(24):5840-1, 2005.
Chung, E.J., Lee, Sunmin, L., Sausville, E.A., Ryan, Q., Karp, J.E., Gojo, I., Telford, W., Lee, M., Trepel, J.B.: Histone deacetylase inhibitor pharmacodynamic analysis by mutiparameter flow cytometry. Ann Clin Lab Sci, 35(4):397-406, 2005.
Kaufmann, S.H., Karp, J.E., Letendre, L., Kottke, T.J., Safgren, S., Greer, J., Gojo, I., Atherton, P., Svingen, P.A., Loegering, D.A., Scheffer, G.L., Maliepaard, M., Litzow, M., Sloan, J.A., Reid, J.M., Ames, M.M., Adjei, A.A., Erlichman, C.: Phase I and pharmacological study of infusional topotecan and carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res, 11(18):6641-9, 2005.
Gojo, I., Meisenberg, B., Guo, C., Fassas, A., Murthy, A., Fenton, R., Takebe, N., Heyman, M., Philips, G., Cottler-Fox, M., Sarkodee-Adoo, C., Ruehle, K., French, T., Tricot, G., Rapoport, A.: Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant, 37(1):65-72, 2005.
Karp, JE., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, TS., Greer, J., Briel, J., Smith, BD., Gore, SD., Tidwell, ML, Ross, DD., Wright, JJ., Colevas, AD., Bauer, KS.: Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res, 11(23):8403-12, 2005.
Acharya, M.R., Karp, J.E., Sausville, E.A., Hwang, K., Ryan Q., Gojo, I., Venitz, J., Figg, WD., Sparreboom, A.: Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs, 2006.
